NCT06536374
Folate Study in Men With Advanced Prostate Cancer
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date: Jun 2026 to Dec 2026
- Eligibility criteria expanded, about 19 words
- Site details revised
Notable Lead sponsor: The University of Texas Health Science Center at San Antonio to University of California, San Diegov5 Show 7 more changesShow less
- Primary and study completion dates pushed to Dec 2027
- Start date: Jun 2025 to Jun 2026
- Eligibility criteria expanded, about 19 words
- Primary endpoints: 2 to 1
- Study sites: 2 to 1
- Secondary endpoints shortened, about 24 words
- Study description shortened, about 4 words
- Notable Start date: Nov 2024 to Jun 2025v4
- Notable Start date: Sep 8, 2024 to Nov 2024v3
- Notable Start date: Aug 8, 2024 to Sep 8, 2024v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Safety of Trimethoprim
Timeframe: From first dose of study therapy through 1 month after completion of study therapy.
Arms and interventions
Trimethoprim plus androgen deprivation therapyExperimental
Administration of trimethoprim to reduce folic acid levels at the time of standard of care androgen deprivation therapy.
Standard of Care treatmentNo intervention
Standard of care treatment participants will have no intervention, only their prescribed androgen deprivation therapy.
Drugs: Trimethoprim Tablets
Sites
1 site in 1 country
- University of California, San DiegoLa Jolla, California, United States